| Propensity score weighting population | ||||
---|---|---|---|---|---|
Adjuvant RT N = 143 | Non-RT N = 503 | Standardized difference | |||
n | (%) | n | (%) | ||
Age | |||||
 Mean (SD) | 67.5 | (11.3) | 67.7 | (11.2) | 0.0215 |
 Median (Q1–Q3) | 67 | (57–72) | 67 | (61–77) |  |
 20–69 | 67 | (46.9) | 238 | (47.9) | 0.0096 |
 70+ | 76 | (53.1) | 259 | (52.1) |  |
Diagnosis year | |||||
 2009–2012 | 88 | (50.9) | 250 | (50.3) | 0.0115 |
 2013–2016 | 85 | (49.1) | 247 | (49.7) |  |
CCI scores | |||||
 0 | 44 | (30.8) | 123 | (24.5) | 0.1433 |
 1+ | 99 | (69.2) | 380 | (75.5) |  |
Differentiation | |||||
 I | 20 | (14.0) | 72 | (14.3) | 0.0212 |
 II | 77 | (53.8) | 273 | (54.3) | 0.0311 |
 III | 46 | (32.1) | 158 | (31.4) | 0.0207 |
AJCC pathologic stage | |||||
 II | 17 | (12.8) | 61 | (12.1) | 0.0114 |
 IIIA | 68 | (47.6) | 241 | (47.9) | 0.0162 |
 IIIB–C | 58 | (40.6) | 201 | (40.0) | 0.0142 |
pT | |||||
 pT1 | 9 | (6.3) | 30 | (5.9) | 0.0238 |
 pT2 | 58 | (40.6) | 202 | (40.2) | 0.0149 |
 pT3–4 | 76 | (53.1) | 271 | (53.9) | 0.0130 |
pN | |||||
 pN0 | 57 | (39.8) | 200 | (39.8) | 0.0000 |
 pN1 | 43 | (30.1) | 151 | (30.0) | 0.0013 |
 pN2–3 | 43 | (30.1) | 152 | (30.2) | 0.0001 |
Hypertension | 110 | (76.9) | 387 | (76.9) | 0.0001 |
CAD | 53 | (37.1) | 184 | (36.6) | 0.0092 |
Diabetes | 60 | (42.0) | 215 | (42.7) | 0.0097 |
Anthracycline-based chemotherapy | 76 | (53.1) | 260 | (51.7) | 0.0280 |
Hormone receptor positive | 59 | (41.3) | 229 | (45.5) | 0.0934 |
Trastuzumab use | 69 | (48.3) | 246 | (48.9) | 0.0031 |
Nodal surgery | |||||
 ALND | 87 | (60.8) | 302 | (60.0) | 0.0079 |
 SLNB | 56 | (39.2) | 201 | (40.0) |  |
Hospital level | |||||
 Academic center | 80 | (55.9) | 285 | (56.7) | 0.0181 |
 Nonacademic center | 63 | (44.1) | 218 | (43.3) |  |